Overview

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

Status:
NOT_YET_RECRUITING
Trial end date:
2025-10-20
Target enrollment:
Participant gender:
Summary
The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.
Phase:
PHASE4
Details
Lead Sponsor:
University of Maryland St. Joseph Medical Center
Treatments:
Angiotensin II